过去十年中,全球生物制药产业经历了一场深刻的地缘政治和技术转移。长期以来,美国与欧洲凭借其深厚的科研积累、成熟的监管体系和雄厚的资本支持,在创新药物研发领域占据绝对主导地位。然而,这一格局正在发生根本性变化。近日,Nature Reviews Drug Discovery发表文章,以详实的数据揭示了一个不容忽视的趋势:中国生物制药企业不仅在增强型抗体药物这一前沿领域实现了数量上的赶超,更在研发质量...
Source Link过去十年中,全球生物制药产业经历了一场深刻的地缘政治和技术转移。长期以来,美国与欧洲凭借其深厚的科研积累、成熟的监管体系和雄厚的资本支持,在创新药物研发领域占据绝对主导地位。然而,这一格局正在发生根本性变化。近日,Nature Reviews Drug Discovery发表文章,以详实的数据揭示了一个不容忽视的趋势:中国生物制药企业不仅在增强型抗体药物这一前沿领域实现了数量上的赶超,更在研发质量...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.